BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to include duvelisib (Copiktra) as a category 2A treatment option for cutaneous T-cell ...

Laura Huppert, MD, discusses the results of the phase 3 ASCENT-03 trial, which compared the antibody-drug conjugate ...

In December 2025, the FDA accepted for priority review the supplemental biologics license application for nivolumab-AVD for the treatment of adult and pediatric patients 12 years and older with ...

This preview introduces the central themes of the upcoming Evolving Paradigms in Oncology program focused on targeted therapies and CELMoD agents in multiple myeloma. Dr. Nisha Joseph offers an early ...

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...

RAD 101 demonstrated significant tumor uptake and 92% concordance with MRI in a phase 2b trial, enhancing confidence in its diagnostic potential. The agent targets fatty acid synthase, aiding in ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

Pelareorep combined with standard chemotherapy achieved a 33% objective response rate in KRAS-mutant MSS mCRC, surpassing ...

Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...